Dr. Vishal Gulati is a specialist venture capital investor backing scientists and tech founders bring their innovations to market. Prior to becoming a VC, Vishal  trained as a clinician scientist at University of Oxford and Imperial College which gives him a rare and unique perspective on the journey of scientific discoveries all the way to commercially successful products. Vishal’s investment thesis is based around the convergence of healthcare, data and engineering.

In his venture capital career spanning over two decades, Vishal has held roles at leading venture firms such as Atlas Venture, Oxford Science Enterprises and Molten Ventures (fka Draper Esprit),

Vishal has served on the boards of over fifteen public and private health and life sciences companies; from Horizon Discovery (a leading player in CRISPR gene editing now acquired by Perkin Elmer) to the world’s most scalable DNA synthesis platform (Evonetix). He was an early backer of some of the pioneering European companies in digital health and AI drug discovery space  such as Clue, Ieso Digital Health, Quit Genius, Zoe, Kheiron, Arctoris, Turbine, Relation Therapeutics,  and AI Vivo. His portfolio of over 30 VC and angel investments makes him one of the most active investors in this space.

Vishal chairs the investment committee of Cancer Research UK seed fund, and holds similar roles at The Francis Crick Institute, (KQ Labs), British Heart Foundation, Medical Research Council, and Innovate UK. Vishal also serves on the advisory board of  Reuben College, the newest of the Oxford University Colleges focusing on biology and artificial intelligence.

This site is curated and maintained by Julie Norledge. If you have any questions about its content, please contact her by email.